Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain

Pain Research and Management

Volumn 15, Issue 3, 2010, Pages 169-178

  Gordon, Allan ^a   Rashiq, Saifudin ^b   Moulin, Dwight E ^c   Clark, Alexander J ^d   Beaulieu, André D ^e   Eisenhoffer, John ^f   Piraino, Paula S ^f   Quigley, Patricia ^g   Harsanyi, Zoltan ^f   Darke, Andrew C ^f  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e Centre de Rhumatologie St Louis   (Canada)

^f PURDUE PHARMA L P   (United States)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Buprenorphine; Low back pain; Transdermal system

Indexed keywords

BUPRENORPHINE; CODEINE; CODEINE PLUS PARACETAMOL; NORSPAN; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; FEMALE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; AGED; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; TIME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANALGESICS, OPIOID; BUPRENORPHINE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; PAIN MEASUREMENT; TIME FACTORS;

EID: 77954172228     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/216725     Document Type: Article

References (38)

1. Statistics Canada. Back pain. 〈http://www.statcan.gc.ca/pub/82-619- m/2006003/4053542-eng.htm〉 (Accessed on December 9, 2008).
2. Woolf AD, Pfledger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56.
3. Rossignol M, Arsenault B, Dionne C, et al. Clinic on Low-Back Pain in Interdisciplinary Practice (CLIP) guidelines. Montréal: Direction de santé publique, Agence de la santé et des services sociaux de Montréal, 2007.
4. Toward Optimized Practice. Management of low back pain. 〈http://www.topalbertadoctors.org/cpgs/back-pain.html〉 (Accessed on November 20, 2009).
5. van Tulder MW, Scholten RJ, Koes BW, Deyo RA. Nonsteroidal anti-inflammatory drugs for low back pain: A systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine 2000;25:2501-13.
6. Dapas F, Hartman SF, Martinez L, et al. Baclofen for the treatment of acute low-back syndrome. A double-blind comparison with placebo. Spine 1985;10:345-9.
7. Arbus L, Fajadet B, Aubert D, Morre M, Goldberger E. Activity of tetrazepam (Myolastan R) in low back pain. A double-blind trial vs. placebo. Clin Trials J 1990;27:258-67.
8. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-32.
9. Ofman JJ, MacLean HC, Straus WL, et al. A meta-analysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12.
10. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
11. Health Canada Advisory. Safety information regarding selective COX-2 inhibitor NSAIDs: Vioxx (rofecoxib), Celebrex (celecoxib), Bextra (valdecoxib), Mobicox (meloxicam) and generic forms of meloxicam, 2004. 〈http://www.hc- sc.gc.ca/ahc-asc/media/advisories-avis/-2004/2004-69-eng.php〉 (Accessed on April 27, 2010).
12. Health Canada Advisory. Health Canada has asked Pfizer to suspend sales of its drug Bextra and informs Canadians of new restrictions on the use of Celebrex, 2005. 〈http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/- 2005/2005-17-eng.php〉 (Accessed on April 27, 2010).
13. Antman EM, Bennett JS, Daugherty A, Furgberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs. An update for Clinicians. A scientific statement from the American Heart Association. Circulation 2007;115:1634-42.
14. Goodkin K, Guillion CM. Antidepressants for the relief of chronic pain: Do they work? Ann Behav Med 1989;11:83-101.
15. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: A meta-analysis of 39 placebo-controlled studies. Pain 2003;49:205-19.
16. Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999;83:137-45.
17. Urquhart DM, Hoving JL, Assendelft WWJJ, Roland M, van Tulder MW. Antidepressants for non-specific low back pain (Review). Cochrane Database Syst Rev 2008;(1):CD001703. (Pubitemid 351807492)
18. Chou R, Fanciullo GJ, Fine PG, et al. American Pain Society opioid treatment guidelines: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30.
19. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005;6:107-12. (Pubitemid 40590522)
20. Russo MA, Wasiak J. A clinical snapshot of transdermal buprenorphine in pain management. Eur J Pain 2007;1:74-7.
21. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13:219-30.
22. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627-32.
23. Cowan A, Friderichs E, Strassburger W, Raffa RB. Basic pharmacology of buprenorphine. In: Budd K, Raffa R, eds. Buprenorphine - The Unique Opioid Analgesic. Stuttgart: Thieme Verlag KG, 2005:92-101.
24. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313.
25. Lewis JW. Clinical pharmacology of buprenorphine in relation to its use as an analgesic. In: Buprenorphine: Combatting Drug Abuse With a Unique Opioid. New York: Wiley-Liss Inc, 1995:151-63.
26. Kögel B, Christoph T, Strassburger W, Friderichs E. Interaction of μ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain 2005;9:599-611. (Pubitemid 41219791)
27. Christoph T, Kogel B, Schiene K, Meen M, De Vry J, Frederichs E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005;507:87-98. (Pubitemid 40126844)
28. Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 μg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: A 12-week, randomized, open label, controlled, parallel-group noninferiority study. Clin Ther 2009;31:503-13.
29. Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: A multicentre, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin Ther 2007;29:2179-93.
30. Pollard CA. Preliminary validity study for the pain disability index. Percept Mot Skills 1984;59:974.
31. Tait RC, Chibnall JT, Krause S. The Pain Disability Index: Psychometric properties. Pain 1990;40:171-82. (Pubitemid 20070786)
32. Kopec JA, Esdaile JM, Abrahamowicz M, et al. The Quebec Back Pain Disability Scale. Spine 1995;20:341-52.
33. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). Conceptual framework and item selection. Medical Care 1992;30:473-83.
34. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58. (Pubitemid 33016608)
35. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94.
36. Moore A, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomized controlled trials of analgesics. Pain 1996;66:229-37.
37. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8. (Pubitemid 37162475)
38. Sibley J, Kelly A, Rashiq S, et al. Controlled release oxycodone and acetaminophen plus codeine in chronic low back pain. In: Abstracts of the 10th World Congress on Pain. San Diego: International Association for the Study of Pain, 2002:429.